A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Subcutaneous Tislelizumab
DRUG: Intravenous Tislelizumab
DRUG: Cisplatin
DRUG: Leucovorin
DRUG: 5-fluorouracil (5-FU)
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

BeOne Medicines